Fluorine-18 (18F) is a fluorine radioisotope, a significant source of positrons. It is mostly produced with a cyclotron primarily by proton irradiation of a stable isotope of oxygen, 18O. Fluorine-18 is the most commonly used radioisotope in the positron emission tomography (PET) radiopharmaceuticals in clinical procedures. PET imaging has become a significant way to study physiological, biochemical, and pharmacological functions in humans. It is a non-invasive imaging technique that can measure the concentration of the tracer in tissues accurately due to its high sensitivity and high spatial resolution. Its physical and nuclear features, along with high distinct activity and ease of large-scale production, and thus the radiochemical labeling and molecular imaging seem more engaging. The significant increase in fluorine-18 radiotracers for PET imaging emphasizes the need for simplistic and efficient 18F-labeling procedures. Thus, the increasing need for PET imagining in healthcare sectors is driving the demand for the global fluorine-18 market during the forecast period.
In radiochemistry, the favorable nuclear and physical characteristics of fluorine-18, including high positron decay ratio, comparatively short half-life, and low positron energy have gained higher popularity in recent years. The global market has witnessed several radio synthetic methods generated for the embodiment of this radionuclide into biologically relevant and stimulating molecules ranging from drug-like molecules to antibodies and oligonucleotides, due to the nuclear properties and the ability to incorporate fluorine-18 in large quantities. Furthermore, fluorine-18 is being widely used in various applications in the field of oncology, neurology, and cardiology. The rise in the use of fluorine-18 in a variety of sectors is driving the global fluorine-18 market.
To know the scope of our report Get a Sample on Fluorine-18 Market
The COVID-19 pandemic has had a strong impact on almost every industry segment, including healthcare systems and diagnostic imaging services. As per the Radiological Society of North America, more than 40% to 90% decline in the medical imaging practices were recorded in 2020. The same slump has been recorded in various regions during the first wave of the pandemic. However, there was a limited study on the impact on the PET designated fluorine-18 market, which reported a slowdown in the demand for fluorine-18 during the first wave of coronavirus. The nuclear medicinal studies show a decrease in the number of PET-CT scans across the globe in the previous years and a halt in the growth rate during the first quarter of 2021. In the middle of the COVID-19 crisis, the number of ambulatories imaging decreased drastically, and optional imaging services were shut for a while. Besides, several regulations had to be updated in hospitals and radiology departments, regarding COVID-19 testing and PPE availability, and experts and managers had to be prepared to handle this new situation effectively.
In order to study the effects and infections of the COVID-19 virus, the fluorine-18 fluorodeoxyglucose PET-CT has been suggested as a non-invasive imaging method for detecting infectious or inflammatory diseases. The ability of 18F-FDG PET/CT to recognize sites of inflammation and infection is essentially related to the glycolytic activity of the cells involved in the inflammatory response. Thus, the producers of fluorine-18 for its medical applications are permitted to keep the production running with all the safety and precautionary measures to ensure the wellbeing of the workers. Furthermore, the rapid distribution of COVID-19 vaccines across various nations ensures the restoration of market and production in a short period. Moreover, the rising immediate demand for PET/CT scan and other fluorine-18 applications is anticipating growth of the fluorine-18 market during the forecast period.
Get a glimpse of the in-depth analysis through our Report Brochure
Expensive Setup Cost Likely to Hamper Fluorine-18 Market Growth
The positron emission tomography (PET) using fluorine-18 has been used with enhanced regularity in the care of patients with soft tissue sarcomas to predict the harmful potential of tumors, the diagnosis for survival, and response to chemotherapy. Imaging with PET has been proven to precisely detect primary tumors as well as lymph node and bone metastases in patients with sarcomas. In soft tissue sarcomas, changes in tumor fluorine-18-FDG uptake correlate significantly with the histopathological response, risk of tumor recurrence, and survival. Thus, PET using ([18] F-FDG) is emerging as a significant imaging modality in the administration of patients with soft tissue sarcomas. Moreover, FDG PET-CT is increasingly being used in various non-oncologic specialties such as cardiology, neurology, and cognitive neuroscience, which is contributing to the increasing demand for the fluorine-18 market.
Major factors driving the growth of the global fluorine-18 market include increase in the rate of cancer across the globe. The PET-CT test helps to diagnose cancer and provides more data, including whether a tumor is benign or malignant, and the response of cancer to treatment. However, the FDG-PET can be expensive and thus, lack availability. Moreover, the cost of installing the PET/CT scan facility with cyclotron is around US$ 5 Mn to US$ 6 Mn. These factors are limiting the expansion of the fluorine-18 market. Nevertheless, with advancements in research and technology and increase in demand for PET-CT imaging across the world, the manufacturers are now focusing on affordable setup measures. Thus, the fluorine-18 market is expecting a heavy demand from developing countries during the forecast period.
The global increase in the frequency and the prevalence of diseases such as cancer, Alzheimer’s, and cardiovascular diseases are generating demand for more precise diagnosis, driving the demand for F-18 isotopes. In addition, the high demand for cancer scan procedures in the developed countries is driving the FDG segment to dominate the global market during the forecast period. Moreover, the growing preference of individuals due to rising health awareness to perform PET/CT scans is one of the key factors propelling the market growth. Furthermore, Asia Pacific countries, including India and China are offering notable opportunities to F-18 producers, owing to the rise in the demand for use in health testing purposes. Hence, the global fluorine-18 market is projected to cross US$ 3 Bn by 2030, expanding at a CAGR of 7.5% from 2021 to 2031.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
The future growth of the global fluorine-18 market can be credited to the rise in inclination toward diagnosis with radionuclides medicine, through PET-CT scan, as it is a well-established non-invasive imaging tool for studying disease development/progression. Moreover, PET-CT scans are proving conducive to evaluate cancer treatment more effectively. Therefore, an increasing number of doctors is preferring to carry out F18-based tests to check abnormalities of cancer cells, which offer significant opportunities for suppliers in the global market. However, the setup cost for the PET-CT system can be expensive for smaller sectors and regions. Thus, manufacturers are intensifying their use of materials to make devices more affordable. These will lead to the expansion of the fluorine-18 market in developing nations.
Fluorine-18 Market – Segmentation
TMR’s study on the global fluorine-18 market includes information divided into three segments: product, end user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global fluorine-18 market have been discussed in detail.
| Product |
|
| End User |
|
| Region |
|
Fluorine-18 market was valued over US$ 1.5 Bn in 2020 and to exceed valuation of US$ 3 Bn by 2031
Fluorine-18 market is projected to expand at a CAGR of 7.5% from 2021 to 2031
Fluorine-18 market is driven by increasing need for PET imagining in healthcare sectors and increase in the rate of cancer across the globe
The FDG segment is expected to account for a major share of the global fluorine-18 market by 2031, due to the increase in demand for PET/CT scan in oncology
Key players in the global fluorine-18 market include Lantheus Holdings, Inc., Siemens Healthineers, Advanced Accelerator Applications (a Novartis AG Company), GE Healthcare (General Electric Company), Blue Earth Diagnostics (A Bracco Imaging Company)
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Fluorine-18 Market
4. Market Overview
4.1. Introduction & Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Fluorine-18 Market Analysis and Forecast, 2017–2031
5. Market Outlook
5.1. Radioactive Material Transport Guidelines
5.2. Radiation Protection Guidelines
5.3. Operating Cost and Pricing Analysis- PET/CT Scan and Fluorine-18 Dose
5.4. Number of PET/CT Scan Installed
5.5. COVID-19 Impact Analysis
5.6. Number of Radiotherapy Centers, by Major Countries
5.7. Pricing Analysis, by Major Brands
5.8. PET Tracers Clinical Trails
6. Global Fluorine-18 Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Global Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031
6.2.1. FDG
6.2.2. NaF
6.2.3. Others
6.3. Global Fluorine-18 Market Attractiveness Analysis, by Product
7. Global Fluorine-18 Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Global Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
7.2.1. Hospitals
7.2.2. Diagnostic Centers
7.2.3. Others
7.3. Global Fluorine-18 Market Attractiveness Analysis, by End-user
8. Global Fluorine-18 Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Fluorine-18 Market Value (US$ Mn) Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Fluorine-18 Market Attractiveness Analysis, by Region
9. North America Fluorine-18 Market Analysis and Forecast
9.1. Introduction
9.2. North America Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031
9.2.1. FDG
9.2.2. NaF
9.2.3. Others
9.3. North America Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Diagnostic Centers
9.3.3. Others
9.4. North America Fluorine-18 Market Value (US$ Mn) Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. North America Fluorine-18 Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By End-user
9.5.3. By Country
10. Europe Fluorine-18 Market Analysis and Forecast
10.1. Introduction
10.2. Europe Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031
10.2.1. FDG
10.2.2. NaF
10.2.3. Others
10.3. Europe Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
10.3.1. Hospitals
10.3.2. Diagnostic Centers
10.3.3. Others
10.4. Europe Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Fluorine-18 Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Fluorine-18 Market Analysis and Forecast
11.1. Introduction
11.2. Asia Pacific Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031
11.2.1. FDG
11.2.2. NaF
11.2.3. Others
11.3. Asia Pacific Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
11.3.1. Hospitals
11.3.2. Diagnostic Centers
11.3.3. Others
11.4. Asia Pacific Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Fluorine-18 Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Fluorine-18 Market Analysis and Forecast
12.1. Introduction
12.2. Latin America Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031
12.2.1. FDG
12.2.2. NaF
12.2.3. Others
12.3. Latin America Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
12.3.1. Hospitals
12.3.2. Diagnostic Centers
12.3.3. Others
12.4. Latin America Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Fluorine-18 Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Fluorine-18 Market Analysis and Forecast
13.1. Introduction
13.2. Middle East & Africa Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031
13.2.1. FDG
13.2.2. NaF
13.2.3. Others
13.3. Middle East & Africa Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
13.3.1. Hospitals
13.3.2. Diagnostic Centers
13.3.3. Others
13.4. Middle East & Africa Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Fluorine-18 Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Position Analysis, by Company, 2019
14.2. Company Profiles
14.2.1. Lantheus Holdings, Inc.
14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.1.2. Growth Strategies
14.2.1.3. SWOT Analysis
14.2.2. Siemens Healthineers
14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.2.2. Growth Strategies
14.2.2.3. SWOT Analysis
14.2.3. Advanced Accelerator Applications (a Novartis AG Company)
14.2.3.1. Company Overview (HQ, Business Segments)
14.2.3.2. Growth Strategies
14.2.3.3. SWOT Analysis
14.2.4. GE Healthcare
14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.4.2. Growth Strategies
14.2.4.3. SWOT Analysis
14.2.5. Blue Earth Diagnostics (A Bracco Imaging Company)
14.2.5.1. Company Overview (HQ, Business Segments)
14.2.5.2. Growth Strategies
14.2.5.3. SWOT Analysis
14.2.6. Jubilant Pharma Limited
14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.6.2. Growth Strategies
14.2.6.3. SWOT Analysis
14.2.7. China lsotope & Radiation Corporation
14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.7.2. Growth Strategies
14.2.7.3. SWOT Analysis
14.2.8. Eli Lilly and Company
14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.8.2. Growth Strategies
14.2.8.3. SWOT Analysis
14.2.9. Curium Pharma
14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.9.2. Growth Strategies
14.2.9.3. SWOT Analysis
14.2.10. Yantai Dongcheng Pharmaceutical Group Co., Ltd.
14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.10.2. Growth Strategies
14.2.10.3. SWOT Analysis
List of Tables
Table 01: North America Installed Base
Table 02: Europe Installed Base
Table 03: Europe Installed Base
Table 04: Asia Pacific and RoW Installed Base
Table 05: Number of Radiotherapy Centers, by Country
Table 06: PET tracers in clinical trials
Table 07: PET tracers in clinical trials
Table 08: PET tracers in clinical trials
Table 09: PET tracers in clinical trials
Table 10: PET tracers in clinical trials
Table 11: PET tracers in clinical trials
Table 12: PET tracers in clinical trials
Table 13: PET tracers in clinical trials
Table 14: Global Fluorine-18 Market Revenue (US$ Mn) Forecast, by Product, 2017–2031
Table 15: Global Fluorine-18 Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 16: Global Fluorine-18 Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 17: North America Fluorine-18 Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 18: North America Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 19: North America Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 20: Europe Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 21: Europe Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 22: Europe Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 23: Asia Pacific Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 24: Asia Pacific Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 25: Asia Pacific Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 26: Latin America Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Latin America Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 28: Latin America Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 29: Middle East & Africa Fluorine-18 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 30: Middle East & Africa Fluorine-18 Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 31: Middle East & Africa Fluorine-18 Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Fluorine-18 Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 02: Global Fluorine-18 Market Value Share, by Region, 2020
Figure 03: Global Fluorine-18 Market Value Share Analysis, by Product, 2020 and 2031
Figure 04: Global Fluorine-18 Market Revenue (US$ Mn), by FDG, 2017–2031
Figure 05: Global Fluorine-18 Market Revenue (US$ Mn), by NaF, 2017–2031
Figure 06: Global Fluorine-18 Market Revenue (US$ Mn), by Others, 2017–2031
Figure 07: Global Fluorine-18 Market Attractive Analysis, by Product, 2021–2031
Figure 08: Global Fluorine-18 Market Value Share Analysis, by End-user, 2020 and 2031
Figure 09: Global Fluorine-18 Market Revenue (US$ Mn), by Hospitals, 2017–2031
Figure 10: Global Fluorine-18 Market Revenue (US$ Mn), by Diagnostic Centers, 2017–2031
Figure 11: Global Fluorine-18 Market Revenue (US$ Mn), by Others, 2017–2031
Figure 12: Global Fluorine-18 Market Attractive Analysis, by End-user, 2021–2031
Figure 13: Global Fluorine-18 Market Value Share Analysis, by Region, 2020 and 2031
Figure 14: Global Fluorine-18 Market Attractiveness Analysis, by Region, 2021–2031
Figure 15: North America Fluorine-18 Market Value (US$ Mn) Forecast, 2017–2031
Figure 16: North America Fluorine-18 Market Value Share Analysis, by Country, 2020 and 2031
Figure 17: North America Fluorine-18 Market Attractiveness Analysis, by Country, 2021–2031
Figure 18: North America Fluorine-18 Market Value Share Analysis, by Product, 2020 and 2031
Figure 19: North America Fluorine-18 Market Attractiveness Analysis, by Product, 2021–2031
Figure 20: North America Fluorine-18 Market Value Share Analysis, by End-user, 2020 and 2031
Figure 21: North America Fluorine-18 Market Attractiveness Analysis, by End-user, 2021–2031
Figure 22: Europe Fluorine-18 Market Value (US$ Mn) Forecast, 2017–2031
Figure 23: Europe Fluorine-18 Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 24: Europe Fluorine-18 Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 25: Europe Fluorine-18 Market Value Share Analysis, by Product, 2020 and 2031
Figure 26: Europe Fluorine-18 Market Attractiveness Analysis, by Product, 2021–2031
Figure 27: Europe Fluorine-18 Market Value Share Analysis, by End-user, 2020 and 2031
Figure 28: Europe Fluorine-18 Market Attractiveness Analysis, by End-user, 2021–2031
Figure 29: Asia Pacific Fluorine-18 Market Value (US$ Mn) Forecast, 2017–2031
Figure 30: Asia Pacific Fluorine-18 Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 31: Asia Pacific Fluorine-18 Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 32: Asia Pacific Fluorine-18 Market Value Share Analysis, by Product, 2020 and 2031
Figure 33: Asia Pacific Fluorine-18 Market Attractiveness Analysis, by Product, 2021–2031
Figure 34: Asia Pacific Fluorine-18 Market Value Share Analysis, by End-user, 2020 and 2031
Figure 35: Asia Pacific Fluorine-18 Market Attractiveness Analysis, by End-user, 2021–2031
Figure 36: Latin America Fluorine-18 Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Latin America Fluorine-18 Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 38: Latin America Fluorine-18 Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 39: Latin America Fluorine-18 Market Value Share Analysis, by Product, 2020 and 2031
Figure 40: Latin America Fluorine-18 Market Attractiveness Analysis, by Product, 2021–2031
Figure 41: Latin America Fluorine-18 Market Value Share Analysis, by End-user, 2020 and 2031
Figure 42: Latin America Fluorine-18 Market Attractiveness Analysis, by End-user, 2021–2031
Figure 43: Middle East & Africa Fluorine-18 Market Value (US$ Mn) Forecast, 2017–2031
Figure 44: Middle East & Africa Fluorine-18 Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 45: Middle East & Africa Fluorine-18 Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 46: Middle East & Africa Fluorine-18 Market Value Share Analysis, by Product, 2020 and 2031
Figure 47: Middle East & Africa Fluorine-18 Market Attractiveness Analysis, by Product, 2021–2031
Figure 48: Middle East & Africa Fluorine-18 Market Value Share Analysis, by End-user, 2020 and 2031
Figure 49: Middle East & Africa Fluorine-18 Market Attractiveness Analysis, by End-user, 2021–2031
Figure 50: Fluorine 18-Market Ranking Analysis
Figure 51: Siemens Healthineers AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 52: Siemens Healthineers AG Breakdown of Net Sales (%), by Region, 2020
Figure 53: Siemens Healthineers AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 54: Siemens Healthineers AG Breakdown of Net Sales (%), by Business Segment, 2020
Figure 55: Lantheus Holdings, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019
Figure 56: Lantheus Holdings, Inc. Breakdown of Net Sales (%), by Region/Country, 2019
Figure 57: Lantheus Holdings, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 58: Jubilant Pharma Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020
Figure 59: Jubilant Pharma Limited Breakdown of Net Sales (%), by Region/Country, 2020
Figure 60: Jubilant Pharma Limited Breakdown of Net Sales (%), by Business Segment, 2020
Figure 61: Jubilant Pharma Limited Breakdown of Net Sales (%), by Specialty Pharmaceuticals, 2020
Figure 62: China lsotope & Radiation Corporation - Revenue (US$ Mn) and Y-o-Y Growth (%), 2019–2020
Figure 63: China lsotope & Radiation Corporation - Breakdown of Net Sales (%), by Business Segment, 2020
Figure 64: GE Healthcare Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2020
Figure 65: GE Healthcare Breakdown of Net Sales (%), by Region/Country, 2020
Figure 66: GE Healthcare Breakdown of Net Sales (%), by Business Segment, 2020
Figure 67: GE Healthcare R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018-2020
Figure 68: Eli Lilly and Company Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020
Figure 69: Eli Lilly and Company R&D Intensity - Company Level, 2018–2020
Figure 70: Eli Lilly and Company Breakdown of Net Sales, by Region, 2020
Figure 71: Eli Lilly and Company Breakdown of Net Sales, by Therapeutic Area, 2020
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Fluorine-18 Market
